Rubric Capital Management LP
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1687509
NEW YORK, NY
Position in PTGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$45,110,989
+$38,248,245 QoQ
Shares Held
427,998
+116.1% QoQ
Ownership
0.661%
of shares outstanding
% of Portfolio
0.56%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rubric Capital Management LP holds $1,431,610,576 across 20 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARQT |
Arcutis Biotherapeutics, Inc.
|
8,271,577 | $216,880,748 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
6,000,000 | $212,340,000 | |
| 3 | ZYME |
Zymeworks Inc.
|
7,000,000 | $182,980,000 | |
| 4 | NRIX |
Nurix Therapeutics, Inc.
|
7,227,778 | $175,345,894 | |
| 5 | MGTX |
MeiraGTx Holdings plc
|
9,100,000 | $122,941,000 | |
| 6 | ARDX |
Ardelyx, Inc.
|
16,202,700 | $82,633,770 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
9,339,414 | $78,170,895 | |
| 8 | MNKD |
Mannkind Corp
|
18,000,000 | $76,680,000 |
All Filings in PTGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $45,110,989 | 427,998 | Shares | Sole | 2026-05-15 | |
| 2024-06-30 | $6,862,744 | 198,059 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $5,729,846 | 198,059 | Shares | Sole | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||